LQDA - NASDAQ
Liquidia Corporation
$55.69
+1.5%Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
At a Glance
Live SnapshotLiquidia Corporation Management Team
Ms. Dana Boyle
Chief Accounting Officer
Mr. Jason Adair
Chief Business Officer
Mr. Scott Moomaw
Chief Commercial Officer
Dr. Roger A. Jeffs Ph.D.
Chief Executive Officer & Director
Compensation
$1,217,780
Ms. Sarah Krepp SPHR
Chief Human Resources Officer
Dr. Rajeev Saggar M.D.
Chief Medical Officer
Mr. Michael Kaseta
Chief Operating Officer & Chief Financial Officer
Compensation
$835,940
Mr. Russell Schundler
General Counsel & Corporate Secretary
Compensation
$729,796
Mr. Michael Hunter
Senior Vice President of Manufacturing Operations
Mr. Frank Bartolini
Senior Vice President of Market Access
Mr. Michael Post
Senior Vice President of Marketing
Ms. Sarah Krepp SPHR
Senior Vice President of People & Culture
Liquidia Corporation Insider Positioning
During the last 12 months, insiders have purchased $318K and sold $73.98M worth of LQDA shares, resulting in $73.67M of net selling activity.
3 Months
5.3K
317.89K
934.8K
41.44M
-41.1M
-$41.12M
3-6 Months
0
0.00
217.0K
8.10M
-8.1M
-$8.10M
6-9 Months
0
0.00
230.9K
6.06M
-6.1M
-$6.06M
9-12 Months
0
0.00
722.2K
18.38M
-18.4M
-$18.38M
Top Buyers
Caligan Partners Lp
Director, 10 Percent Owner, Other: See Remarks
$318K
Top Sellers
Jeffs Roger
Director, Officer: Chief Executive Officer
$23.48M
Kaseta Michael
Officer: Cfo And Coo
$12.30M
Manning Paul B
Director
$11.67M
Moomaw Scott
Officer: Chief Commercial Officer
$6.10M
Bloch Stephen M
Director
$5.05M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $73.67M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
LQDA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 16, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | June 17, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | June 20, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 15, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 16, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 30, 2021 | June 17, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.